Further experiments should be performed to investigate the effects of GNAI3 on immune cells within the TME in gliomas to develop personalized approaches such as vaccinations and to explore multiple clinical trials investigating immunotherapy combination studies. This evidence concerns the gene GNAI3 and central nervous system cancer.